Back to Search
STEPHEN GREENSPAN, M.D.
M.D.
Internal Medicine Physician
NPI: 1255366845IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
MD050204L(PA)D68252(MD)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
JEFFERSON MEDICAL COLLEGE OF THOMAS JEFFERSON UNIVERSITY
Class of 1987
Research & Publications (20)
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
PMID 18427147·J Clin Oncol·2008
2-rct
Approach to the prostate cancer patient with bone disease.
PMID 18178905·J Clin Endocrinol Metab·2008
5-case
Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women.
PMID 18519174·Bone·2008
2-rct
Guidelines for early identification, screening, and clinical management of children with autism spectrum disorders.
PMID 18381546·Pediatrics·2008
6-review
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.
PMID 18802155·J Clin Oncol·2008
2-rct
The interdisciplinary council on developmental and learning disorders diagnostic manual for infants and young children - an overview.
PMID 18516310·J Can Acad Child Adolesc Psychiatry·2008
8-other
Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
PMID 17047022·J Clin Endocrinol Metab·2007
2-rct
Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial.
PMID 16059624·J Bone Miner Res·2005
3-trial
The effect of hormone replacement on physical performance in community-dwelling elderly women.
PMID 16271907·Am J Med·2005
4-observational
Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
PMID 15713726·J Clin Endocrinol Metab·2005
3-trial
Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
PMID 12759324·JAMA·2003
3-trial
Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
PMID 12374248·Mayo Clin Proc·2002
3-trial
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
PMID 12458987·Ann Intern Med·2002
3-trial
Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial.
PMID 12020142·Ann Intern Med·2002
3-trial
A sex police for adults with "mental retardation"? Comment on Spiecker and Steutel.
PMID 15027440·J Moral Educ·2002
8-other
Clinical performance of a highly portable, scanning calcaneal ultrasonometer.
PMID 11444088·Osteoporos Int·2001
8-other
Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis.
PMID 11748342·J Clin Densitom·2001
8-other
Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women.
PMID 11061497·J Clin Endocrinol Metab·2000
3-trial
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design.
PMID 19468663·Osteoporos Int·2009
4-observational
Assessment and diagnosis of mental retardation in death penalty cases: introduction and overview of the special "Atkins" issue.
PMID 19430989·Appl Neuropsychol·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 6315-17 WOODLAND AVE
PHILADELPHIA, PA 19142 - Phone
- (215) 726-1870
Quick Facts
- NPI
- 1255366845
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 39
- Publications
- 20
Are you this provider?
Claim Your Profile